Rosiglitazone is a safe and effective treatment option of new‐onset diabetes mellitus after renal transplantation

The purpose of this study was to assess the safety and efficacy of the insulin sensitizer rosiglitazone in patients with new‐onset diabetes mellitus (NODM) after renal transplantation. Twenty‐two patients with NODM after renal transplantation were selected to receive rosiglitazone therapy. All patients received prednisone, 15 patients were treated with tacrolimus and seven patients received cyclosporine A. For 16 of the 22 patients treatment with rosiglitazone therapy was successful and mean fasting blood glucose decreased from 182 ± 17 to 127 ± 7 mg/dl. Six patients were not treated successfully with rosiglitazone alone, one patient needed a second oral antidiabetic agent and four patients insulin therapy. In one patient rosiglitazone was stopped because of edema after 5 days. There were no changes either in serum creatinine concentrations, or cyclosporine and tacrolimus blood levels respectively. Treatment with rosiglitazone appears to be safe and effective in patients with NODM after renal transplantation.

[1]  D. Baldwin,et al.  Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. , 2004, Transplantation.

[2]  Y. Hung,et al.  Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  Bertram L Kasiske,et al.  New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. , 2003, Transplantation.

[4]  A. Hartmann,et al.  Diagnosing PTDM 1 , 2003 .

[5]  M. Freed,et al.  Pharmacokinetics of Rosiglitazone in Patients with End-Stage Renal Disease , 2002, The Journal of international medical research.

[6]  S. Gabriel,et al.  Posttransplantation diabetes: a systematic review of the literature. , 2002, Diabetes care.

[7]  D. Gerber,et al.  Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. , 2002, Transplantation.

[8]  P. Raskin,et al.  Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes , 2000, Diabetologia.

[9]  B. Wolffenbuttel,et al.  Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[10]  J. Fang,et al.  Diabetes mellitus after renal transplantation. , 1998, Transplantation proceedings.

[11]  Joshua Miller,et al.  A Comparison Of Tacrolimus (fk506) And Cyclosporine For Immunosuppression After Cadaveric Renal Transplantation1 , 1997 .

[12]  P. Lang,et al.  Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors. , 1996, Transplantation.

[13]  T. Fujimura,et al.  TRANSCRIPTIONAL INHIBITION OF INSULIN BY FK506 AND POSSIBLE INVOLVEMENT OF FK506 BINDING PROTEIN‐12 IN PANCREATIC β-CELL , 1995, Transplantation.

[14]  K. Ohara,et al.  THE EFFECTS OF FK506 AND CYCLOSPORINE ON THE EXOCRINE FUNCTION OF THE RAT PANCREAS , 1992, Transplantation.

[15]  E. Friedman,et al.  Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors. , 1991, Transplantation.

[16]  G. Burke,et al.  POSTTRANSPLANT HYPERGLYCEMIA: Increased Incidence in Cyclosporine‐Treated Renal Allograft Recipients“ , 1989, Transplantation.

[17]  B. Kasiske,et al.  NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES , 2003 .

[18]  A. Hartmann,et al.  Diagnosing PTDM. , 2002, Transplantation.

[19]  S. Mudaliar,et al.  New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. , 2001, Annual review of medicine.

[20]  J. Pirsch,et al.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. , 1997, Transplantation.

[21]  E. Friedman,et al.  Posttransplant diabetes in kidney transplant recipients. , 1985, American journal of nephrology.